AnaptysBio, Inc. Names Vice President to Lead Therapeutic Antibody Preclinical Development Efforts

SAN DIEGO--(BUSINESS WIRE)--AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced the appointment of Dr. Mohammad Tabrizi as vice president of preclinical development. Tabrizi brings extensive experience in the research and development of monoclonal antibodies to the San Diego-based company as it continues to implement its strategic growth plan for 2009 and beyond.

Back to news